The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

糖尿病合并细菌性肝脓肿的临床特点和治疗

目的:探讨糖尿病合并细菌性肝脓肿(diabetic bacterial hepatic abscess,DBHA)的临床特点和治疗方法.方法:对26例DBHA和36例非糖尿病肝脓肿(nondiabetic hepatic abscess,NDHA)患者的临床特点和治疗转归进行回顾性对比分析.结果:26例DBHA均为2型糖尿病患者,老年人居多,36例NDHA以中年人为多;DBHA组无定位症状者10例(38%),NDHA组6例(17%),两组比较差异有统计学意义,P＜0.05;DBHA组的病原菌主要为肺炎克雷伯杆菌(6例)、大肠埃希菌(2例),NDHA组为大肠埃希菌(3例)、星座链球菌(1例)、肺炎克雷伯杆菌(1例);DBHA组治愈率(35%)较NDHA组(67%)低,DBHA组平均住院时间(31日)较NDHA组(22日)长,两组比较差异均有统计学意义,均为P＜0.05;DBHA组行保守治疗患者的平均住院时间为37日,较行肝脓肿穿刺的患者长(27日),比较差异有统计学意义,P＜0.05.结论:DBHA是老年糖尿病患者的严重感染,较NDHA发病隐匿、治愈率低、住院时间长,及时行脓肿穿刺术是缩短DBHA病程的有效治疗方法.     

瑞格列奈对新诊断2型糖尿病患者胰岛β细胞功能及血糖的影响

目的 探讨瑞格列奈短期强化治疗对改善新诊断2型糖尿病(T2DM)患者的胰岛β细胞功能及长期血糖控制的影响. 方法 采用自身前后对照和组间对照方法 ,观察80例空腹血糖(FPG)<11.1 mmol/L,餐后2 h血糖(PG2h)<15 mmol/L,糖化血红蛋白(HbA1c)<10.0%的新诊断T2DM患者接受瑞格列奈(诺和龙)短期强化治疗前后胰岛β细胞对血糖刺激的胰岛素早时相分泌(△I30/△G30比值)、血脂、胰岛素分泌(Homa)指数A、Homa B的变化. 结果 治疗后,75 g口服葡萄糖试验(OGTT)、成功组、中间组、失败组空腹血糖分别从(8.9±1.5)、(8.6±1.6)、(9.0±2.0)mmol/L降至(5.0±1.4)、(6.3±0.7)、(6.5±0.9)mmol/L,餐后0.5 h血糖分别从(12.6± 1.6)、(12.6±1.5)、(12.4±1.3)mmol/L降至(8.4±1.0)、(6.8±0.7)、(8.6±0.9)mmol/L,餐后2h血糖分别从(13.0±1.2)、(13.1±1.3)、(13.3±1.4)mmol/L降至(9.2±0.9)、(6.6±0.7)、(9.2±0.9)mmol/L,差异有统计学意义(P<0.005);△I30/△G30比值;成功组和中间组,失败组分别从1.69±0.31、1.72±0.33和平共处.79±0.36升高到4.47±0.62,4.42±0.46和2.00±0.46均有明显改善(P<0.05);Homa B明显升高(P<0.05),Homa A、三酰甘油(TG)明显下降(P<0.05).其中有21例患者超过6个月(最长达18个月)仅采用生活方式干预,空腹及餐后血糖均维持在正常范围;成功组与失败组相比,在△I30/△G30比值(4.47±0.62与2.0±0.46)、年龄((39±8)岁与(56±9岁)]、诺和龙最终用量[(2.0±1.5)g与(5.0±2.5)g3、血糖达标时间[(32.4±8.0)个月与(53.3±7.6)个月]比较差异均有统计学意义(P<0.05). 结论 短期瑞格列奈强化治疗可以恢复代表胰岛β细胞功能的血糖刺激的胰岛素早时相分泌,重塑胰岛素分泌的生理模式,有效缓解糖尿病病情.     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

2型糖尿病合并脂肪肝与胰岛素抵抗及血脂异常的关系

目的 探讨2型糖尿病（T2DM）患者血脂代谢紊乱及胰岛素抵抗与脂肪肝发病的关系。方法 对我院2003年住院的2型糖尿病患者,根据有无合并脂肪肝分为脂肪肝组和非脂肪肝组,进行空腹血胆固醇（TC）、甘油三酯（TG）、空腹胰岛素（FINS）、空腹血糖（FBG）、餐后2小时血糖（2hPBG）测定,进行HOMA—IR计算,并进行分析。结果 合并脂肪肝组TG、FINS、LDL、HOMA—IR较无合并脂肪肝组升高（P均〈0．05）,而TC、FBG、PBG两组差别无显著性（P〉0．05）,HLD水平降低与脂肪肝呈负相关。结论 2型糖尿病合并脂肪肝组血脂代谢紊乱、胰岛素抵抗更明显。     

糖尿病并发脑神经病变临床分析

糖尿病并发脑神经病变临床上较少见,文献报道亦不多。近7年来,我院收住糖尿病患者833例,其中并发脑神经病变15例,并发率为1.8％(15/833),现总结分析如下。1 临床资料1.1 一般资料 本组15例,男7例,女8例,年龄41～79岁,平均57.7岁。依据1997年全国糖尿病研究专题会议诊断标准,均可诊为糖尿病Ⅱ型。15例患者空腹血糖10.5—47.23mmol/L,平均16.4mmol/L,尿糖+～(?);2例首发以面神经麻痹就诊,     

The effect of repaglinide on blood glucose and islet β-cell function in newly diagnosed type 2 diabetic patients

Objective To explore the effect of repaglinide intensive treatment on islet β-cell function and long-term control of blood glucose in newly diagnosed type 2 diabetic patients. Methods Self-control and inter-group control prospective study was conducted in 80 newly diagnosed type 2 diabetic patients who were treated with short-term repaglinide intensive treatment and islet β-cell function was assessed by 75 g oral glucose tolerance test (OGTT) before and after repaglinide treatment. The changes of △I30/△G30 ratio, blood lipid, HOMA A and HOMA B were examined. Results After treatment, in successful group, middle group and defeat group, the fasting plasma glucose levels were decreased from 8.9±1.5, 8.6±1.6,9.0±2.0 to 5.0±1.4,6.3±0. 7,6.5±0. 9 mmol/L, 0. 5 h postprandial glucose levels were decreased from (12.6±1.6, 12.6±1.5, 12.4±1.3 to 8.4±1.0, 6.8±0. 7, 8. 6±0. 9)mmol/L,and 2 h postprandial glucose levels were decreased from (13.0±1.2, 13. 1±1.3, 13. 3±1.4 to 9.2±0.9, 6.6±0. 7, 9.2±0. 9)mmol/L,respectively (all P <0. 005). The ratio of △I30/△G30 was increased froml. 69±0. 31, 1.72±0. 33, 1.79±0. 36 to 4. 47±0. 62, 4. 42±0.46,12. 00±0.46 in the three groups, respectively (P<0.05). HOMA B was significantly improved (P<0. 05), while triglycerides and HOMA A were decreased(P<0. 05). The levels of fasting blood glucose and postprandial blood glucose in 21 patients were maintained within normal range for more than six months. There were significant differences in the ratio of △I30/△G30, age, repaglinide dosage and the time of reaching target of glucose [4.47±0.62 vs. 2. 0± 0.46; 39±8 vs. 56±9; 2.0±1.5 vs. 5.0±2.5; 32.4±8.0 vs. 53.3±7.6; all P<0.05] between successful group and defeat group. Conclusions The short-term intensive treatment with repaglinide can significantly improve the early secretion phase of insulin and the islet β-cell function, reconstruct of the physiological model of insulin secretion and relieve the disease.     

甲状腺癌术后发生Graves病

目的：总结甲状腺癌术后发生Graves病诊断及治疗经验。方法：回顾性分析10例甲状腺癌术后发生Graves病患的病史，体检，实验室检查，处理方法及随访结果，结果：甲状腺癌患术后出现甲亢症候群，突眼体征，FT3、FT4升高，TSH下降，TRAb升高，甲状腺摄碘率升高以及高峰前移可做出甲状腺癌术后发生Graves病诊断，其中3例采用^131I治疗而愈，余7例采用抗甲状腺药物治疗病情控制。结论：甲状腺癌术后发生Graves病应采用药物或^131I放射治疗。     

非酮症性高渗性糖尿病昏迷合并多脏器功能衰竭21例

非酮症性高渗性糖尿病昏迷合并多脏器功能衰竭２１例温州市第二人民医院内分泌组王敏恩，王怡淳，胡臻非酮症性高诊性糖尿病昏迷（ＮＨＤＣ）合并多脏器功能衰竭（ＭＯＦ）为糖尿病危重并发症。本院１９８２～１９８９年共收治２１例，本文讨论其临床特点和治疗。一、一般...